TECMA SOLUTIONS SPA (TCM.MI) Fundamental Analysis & Valuation

BIT:TCM • IT0005425050

Current stock price

1.695 EUR
+0.16 (+10.06%)
Last:

This TCM.MI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. TCM.MI Profitability Analysis

1.1 Basic Checks

  • In the past year TCM has reported negative net income.
  • In the past year TCM had a positive cash flow from operations.
  • TCM had negative earnings in each of the past 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: TCM reported negative operating cash flow in multiple years.
TCM.MI Yearly Net Income VS EBIT VS OCF VS FCFTCM.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2M -2M -4M -6M

1.2 Ratios

  • TCM has a worse Return On Assets (-10.15%) than 73.91% of its industry peers.
  • The Return On Equity of TCM (-44.17%) is worse than 72.46% of its industry peers.
Industry RankSector Rank
ROA -10.15%
ROE -44.17%
ROIC N/A
ROA(3y)-23.71%
ROA(5y)-21.11%
ROE(3y)-76.5%
ROE(5y)-57.86%
ROIC(3y)N/A
ROIC(5y)N/A
TCM.MI Yearly ROA, ROE, ROICTCM.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100

1.3 Margins

  • TCM has a better Gross Margin (70.81%) than 65.22% of its industry peers.
  • In the last couple of years the Gross Margin of TCM has remained more or less at the same level.
  • TCM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 70.81%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.37%
GM growth 5Y0.75%
TCM.MI Yearly Profit, Operating, Gross MarginsTCM.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. TCM.MI Health Analysis

2.1 Basic Checks

  • TCM does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, TCM has about the same amount of shares outstanding.
  • The number of shares outstanding for TCM has been increased compared to 5 years ago.
  • TCM has a worse debt/assets ratio than last year.
TCM.MI Yearly Shares OutstandingTCM.MI Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M
TCM.MI Yearly Total Debt VS Total AssetsTCM.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M

2.2 Solvency

  • Based on the Altman-Z score of -0.09, we must say that TCM is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of TCM (-0.09) is worse than 72.46% of its industry peers.
  • The Debt to FCF ratio of TCM is 38.71, which is on the high side as it means it would take TCM, 38.71 years of fcf income to pay off all of its debts.
  • TCM has a Debt to FCF ratio (38.71) which is in line with its industry peers.
  • TCM has a Debt/Equity ratio of 1.31. This is a high value indicating a heavy dependency on external financing.
  • The Debt to Equity ratio of TCM (1.31) is worse than 66.67% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.31
Debt/FCF 38.71
Altman-Z -0.09
ROIC/WACCN/A
WACC6.87%
TCM.MI Yearly LT Debt VS Equity VS FCFTCM.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M -5M 10M

2.3 Liquidity

  • TCM has a Current Ratio of 1.81. This is a normal value and indicates that TCM is financially healthy and should not expect problems in meeting its short term obligations.
  • The Current ratio of TCM (1.81) is better than 60.87% of its industry peers.
  • TCM has a Quick Ratio of 1.81. This is a normal value and indicates that TCM is financially healthy and should not expect problems in meeting its short term obligations.
  • TCM has a Quick ratio of 1.81. This is in the better half of the industry: TCM outperforms 73.91% of its industry peers.
Industry RankSector Rank
Current Ratio 1.81
Quick Ratio 1.81
TCM.MI Yearly Current Assets VS Current LiabilitesTCM.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. TCM.MI Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 46.77% over the past year.
  • TCM shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -11.25%.
  • The Revenue has been growing by 10.39% on average over the past years. This is quite good.
EPS 1Y (TTM)46.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80.95%
Revenue 1Y (TTM)-11.25%
Revenue growth 3Y5.53%
Revenue growth 5Y10.39%
Sales Q2Q%-16.78%

3.2 Future

  • TCM is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.09% yearly.
  • Based on estimates for the next years, TCM will show a very negative growth in Revenue. The Revenue will decrease by -18.92% on average per year.
EPS Next Y10.05%
EPS Next 2Y5.09%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-31.99%
Revenue Next 2Y-18.92%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
TCM.MI Yearly Revenue VS EstimatesTCM.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M
TCM.MI Yearly EPS VS EstimatesTCM.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 -0.4

More info and screens

Find the best growth stocksShow best growing peers

5

4. TCM.MI Valuation Analysis

4.1 Price/Earnings Ratio

  • TCM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • TCM is valuated cheaply with a Price/Forward Earnings ratio of 7.66.
  • TCM's Price/Forward Earnings ratio is rather cheap when compared to the industry. TCM is cheaper than 91.30% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 22.62. TCM is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 7.66
TCM.MI Price Earnings VS Forward Price EarningsTCM.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of TCM indicates a somewhat cheap valuation: TCM is cheaper than 66.67% of the companies listed in the same industry.
  • TCM's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 113.4
EV/EBITDA 18
TCM.MI Per share dataTCM.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.09%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TCM.MI Dividend Analysis

5.1 Amount

  • No dividends for TCM!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TCM.MI Fundamentals: All Metrics, Ratios and Statistics

TECMA SOLUTIONS SPA

BIT:TCM (4/15/2026, 7:00:00 PM)

1.695

+0.16 (+10.06%)

Chartmill FA Rating
GICS SectorReal Estate
GICS IndustryGroupEquity Real Estate Investment Trusts (REITs)
GICS IndustryReal Estate Management & Development
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners6.46%
Inst Owner ChangeN/A
Ins Owners43.8%
Ins Owner ChangeN/A
Market Cap14.59M
Revenue(TTM)12.43M
Net Income(TTM)-1.06M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 7.66
P/S 1.17
P/FCF 113.4
P/OCF 13.58
P/B 6.1
P/tB 5837.58
EV/EBITDA 18
EPS(TTM)-0.12
EYN/A
EPS(NY)0.22
Fwd EY13.06%
FCF(TTM)0.01
FCFY0.88%
OCF(TTM)0.12
OCFY7.36%
SpS1.44
BVpS0.28
TBVpS0
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -10.15%
ROE -44.17%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 70.81%
FCFM 1.04%
ROA(3y)-23.71%
ROA(5y)-21.11%
ROE(3y)-76.5%
ROE(5y)-57.86%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.37%
GM growth 5Y0.75%
F-Score5
Asset Turnover1.19
Health
Industry RankSector Rank
Debt/Equity 1.31
Debt/FCF 38.71
Debt/EBITDA 3.66
Cap/Depr 52.75%
Cap/Sales 7.61%
Interest Coverage N/A
Cash Conversion 125.05%
Profit Quality N/A
Current Ratio 1.81
Quick Ratio 1.81
Altman-Z -0.09
F-Score5
WACC6.87%
ROIC/WACCN/A
Cap/Depr(3y)43.83%
Cap/Depr(5y)82.76%
Cap/Sales(3y)11.46%
Cap/Sales(5y)27.44%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80.95%
EPS Next Y10.05%
EPS Next 2Y5.09%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-11.25%
Revenue growth 3Y5.53%
Revenue growth 5Y10.39%
Sales Q2Q%-16.78%
Revenue Next Year-31.99%
Revenue Next 2Y-18.92%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y56.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year115.26%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-84.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-50.61%
OCF growth 3YN/A
OCF growth 5Y-3.89%

TECMA SOLUTIONS SPA / TCM.MI Fundamental Analysis FAQ

What is the ChartMill fundamental rating of TECMA SOLUTIONS SPA (TCM.MI) stock?

ChartMill assigns a fundamental rating of 2 / 10 to TCM.MI.


What is the valuation status for TCM stock?

ChartMill assigns a valuation rating of 5 / 10 to TECMA SOLUTIONS SPA (TCM.MI). This can be considered as Fairly Valued.


Can you provide the profitability details for TECMA SOLUTIONS SPA?

TECMA SOLUTIONS SPA (TCM.MI) has a profitability rating of 1 / 10.


Can you provide the financial health for TCM stock?

The financial health rating of TECMA SOLUTIONS SPA (TCM.MI) is 3 / 10.


What is the earnings growth outlook for TECMA SOLUTIONS SPA?

The Earnings per Share (EPS) of TECMA SOLUTIONS SPA (TCM.MI) is expected to grow by 10.05% in the next year.